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Abstract: Type 2 diabetes is one of the leading causes of morbidity and mortality, consuming 
a significant proportion of public health spending. Oral hypoglycemic agents (OHAs) are the 
frontline treatment approaches after lifestyle changes. However, huge interindividual variation 
in response to OHAs results in unnecessary treatment failure. In addition to nongenetic factors, 
genetic factors are thought to contribute to much of such variability, highlighting the importance 
of the potential of pharmacogenetics to improve therapeutic outcome. Despite the presence of 
conflicting results, significant progress has been made in an effort to identify the genetic mark-
ers associated with pharmacokinetics, pharmacodynamics, and ultimately therapeutic response 
and/or adverse outcomes to OHAs. As such, this article presents a comprehensive review of 
current knowledge on pharmacogenetics of OHAs and provides insights into knowledge gaps 
and future directions.
Keywords: pharmacogenetics, type 2 diabetes, oral hypoglycemic agents, pharmacokinetics, 
pharmacodynamics, response
Introduction
Type 2 diabetes (T2D) is a complex disease characterized by persistent hypergly-
cemia as a result of insufficient insulin secretion, usually in the context of reduced 
insulin action. Frightening trends in morbidity and mortality of the disease are being 
observed. According to a recent estimate, some 382 million people between the ages 
of 20 years and 79 years live with diabetes, increasing to 592 million by 2035.1 T2D 
accounts for 85%–95% of the cases. According to the International Diabetes Federa-
tion, diabetes is the fifth leading cause of death, and it consumes ∼11% of the global 
health care spending.2
Following initial dietary and lifestyle changes, the most common treatment for T2D is 
the addition of oral hypoglycemic agents (OHAs), with a progressive addition of agents 
over time before insulin treatment is required to maintain glycemia at target. Currently 
available treatments include biguanides, sulfonylureas (SUs), meglitinides (glinides), 
thiazolidinediones (TZDs), α-glucosidase inhibitors, glucagon-like peptide (GLP)-1 
receptor (GLP-1R) agonists, dipeptidyl peptidase (DPP)-4 inhibitors, and sodium glucose 
transporter (SGLT)-2 inhibitors. Despite the availability of several OHAs, only 53% of 
Diabetes Mellitus patients achieve a target glycated hemoglobin (HbA1c) of ,7.0%.3
There is a considerable interindividual variability in drug response, measured in 
terms of efficacy or adverse drug outcomes, in T2D. A complex interaction of bio-
logical and nonbiological factors could explain this variability. While adherence to 
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prescribed treatment, access to health care, and prescribing 
practice are some of the nonbiological factors,4 biological 
factors could be either genetic or nongenetic. Nongenetic 
biological factors influencing response to OHAs are related 
to intestinal, hepatic, or renal function in addition to age, sex, 
and body weight. Pharmacogenomics is the study of genetic 
factors affecting efficacy or undesired effects of drugs. In this 
review, we assess the published evidence for the presence 
of gene–drug interactions in T2D and appraise the usage of 
such evidence to understand pharmacokinetics (PK) and/
or pharmacodynamics (PD) of diabetes drugs and predict 
therapeutic response or adverse drug outcomes.
Challenges in the study of drug 
response in diabetes
In designing, conducting, and interpreting pharmacogenet-
ics studies, there are a number of factors that should be 
considered, including how drug response is defined, what 
covariates are included in the model, and how to account for 
difference in baseline HbA1c, the need for large sample size, 
comorbidities, and drug interactions. The field of pharmaco-
genetics is plagued with many positive but very small studies 
that cannot be replicated, with only a few consistent phar-
macogenetic findings. For SUs, the most robust findings are 
for cytochrome P450, family 2, subfamily C, polypeptide 9 
(CYP2C9), ATP-binding cassette, sub-family C, member 8 
(ABCC8), and transcription factor 7-like 2 (TCF7L2), and for 
metformin, they are for ataxia telangiectasia mutated (ATM) 
and possibly for multidrug and toxin extrusion (MATE) 1, 
with no consistent variants associated with response to gli-
tazones, DPP-4 inhibitors, SGLT-2 inhibitors, or GLP-1R 
agonists – in part because no large studies have been done 
in these areas. In this review, we will first highlight the 
challenges in the study of drug response in diabetes before 
reviewing the literature in relation to genetic variation in PK 
and PD of all commonly used diabetes treatments. We high-
light the key findings and whether they replicate or not.
Study design and confounders
Prospective genotype blind studies are optimal for phar-
macogenetic studies. However, they require a large sample 
size and are costly and time consuming. Therefore, the 
majority of published studies are either retrospective or 
case–control in design and therefore at risk of selection bias 
and confounding.
The association between genetic variants and drug 
response may be confounded by multiple factors. Base-
line HbA1c has a strong effect on response and should be 
considered in any model of glycemic response.5 Other factors, 
such as dose, drug group, and kidney and liver function tests, 
may alter magnitude and direction of reported effect sizes. 
Furthermore, adherence, estimated to range from 36%–93% 
in diabetic patients, could also be an important confounder.6 
While it is a reasonable assumption that most covariates that 
alter response are not correlated with genotype, care should 
be taken to evaluate these covariates in any pharmacogenetic 
response models.
Selection of genes/SNPs
To date, most pharmacogenetic studies of OHAs adopted a 
candidate gene approach. Based on the PK and PD knowl-
edge of the agents, genetic polymorphisms in transporter 
genes, metabolizing enzyme genes, and target genes were 
investigated. Apart from the largely consistent associations 
observed between CYP2C9*2/*3, Potassium Channel, 
Inwardly Rectifying Subfamily J, Member 11 (KCNJ11)/
ABCC8, and TCF7L2 for response to SU, no other phar-
macogenetic impact has been robustly established by these 
candidate gene studies. The existence of gene–gene interac-
tion, as suggested by a few recent pharmacogenetic studies of 
metformin response, could be the explanation for some of the 
replication failure as the marginal impact of each individual 
variant would be much smaller and difficult to detect than 
in a true interaction model.
The genetic architecture of drug response, which encom-
passes the frequency, number, and effect size of genetic vari-
ants, has rarely been addressed for any commonly prescribed 
drug. A recent study showed that many common variants 
with small-to-moderate effect sizes together account for 
20%–30% of variance in glycemic response to metformin.7 
Given that these variants are likely to be distributed across 
the genome, a hypothesis-free Genome-Wide Associa-
tion Study (GWAS) approach holds the potential to reveal 
more metformin response variants. Indeed, the only GWAS 
on OHAs published to date reported a robust association 
between glycemic response to metformin and variants at the 
ATM locus, which harbors no established candidate genes.8 
With the ever-reducing cost of genotyping on microarrays, 
more drug response GWAS analyses are expected to reveal 
novel mechanistic insights and/or genetic markers that could 
predict an efficacy or safety of drugs in diabetes.
Sample size and power
When considering drug efficacy, the general disappointing 
lack of consistent replication in the candidate gene studies 
reviewed here suggests that none of the variants examined 
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so far has a large impact on clinical outcomes. If the genetic 
architecture of treatment efficacy by other OHAs is similar 
to that of metformin, which is contributed by many common 
variants with small-to-moderate effect sizes, the large sample 
sizes will be essential to provide an adequate statistical power 
to uncover the variants. Moreover, when multiple variants are 
examined in a single study, such as the gene–gene interac-
tion or GWAS analyses, even larger sample sizes, typically 
in the range of a few thousand, are required to compensate 
the statistical penalty associated with multiple testing. Most 
of the studies reviewed here used a few hundred individuals 
or less (column 4 or 6 in Tables S1–S5), which have prob-
ably resulted in the inconsistent reports, with an overrepre-
sentation of positive results due to the winners’ curse and 
publication bias.9
However, it is worth noting that when considering more 
severe adverse reactions of drugs, such as metformin-induced 
lactic acidosis, a small sample size may be sufficient. This 
is seen most clearly in relation to drug-induced severe liver 
injury where the large impact causal variants were identified 
with just a few dozen samples.10,11 Therefore, genetic screen-
ing of rare severe adverse reactions with small samples is still 
warranted, provided that power calculations are presented to 
inform the range of effect sizes that could be excluded by 
the study design.
Choice and definition of end points
The phenotype for drug response is often variably defined 
depending on the available data that can make comparing the 
findings across the studies difficult. A linear term for HbA1c 
reduction or blood glucose reduction, or a dichotomous vari-
able defined as achieving therapeutic target (HbA1c ,7%) 
over a specified period of time, is the most commonly used 
end point in diabetes. Genetic determinants of safety and 
efficacy to the same drug might vary. However, some safety 
and efficacy measures may overlap and thus be associated 
with the same genes, for example, extreme response to SUs 
and hypoglycemia. The availability of multiple end points 
could increase the chance of selective outcome-reporting 
bias in pharmacogenetic studies. Therefore, consistent and 
functionally relevant response definitions where possible 
publishing a protocol in advance may be helpful.
Obesity and related comorbidities
Suboptimal glycemic control is usually associated with 
greater comorbidities, including hypertension and dys-
lipidemia. The fact that obesity and T2D are strongly linked 
led to the investigation of obesity as a clinical predictor of 
efficacy to OHAs. The first-line drug metformin showed 
similar efficacy in obese and nonobese T2D individuals.12,13 In 
another study, body mass index was not significantly associ-
ated with glycemic response to rosiglitazone, but responders 
had higher body fat percentage than nonresponders.14 Those 
with greater waist-to-hip ratio also showed a better reduction 
of fasting plasma glucose (FPG) and HbA1c when rosiglita-
zone was added to metformin and/or SUs.15
Drug–drug interactions
To achieve adequate glycemic control and treat concurrent 
pathologies, diabetic patients are often on polypharmacy, 
therefore there is a risk of drug–drug interactions.16 The con-
comitant administration of organic cation transporter (OCT) 
1-inhibiting drugs with metformin is reported to increase the 
gut concentration of metformin and gastro intestinal (GI) 
side effects.17 Coadministration of CYP-inhibiting drugs 
with insulin secretagogues risks potentiating hypoglyce-
mia. In healthy volunteers, simultaneous administration of 
gemfibrozil, a lipid-lowering drug that inhibits CYP2C8, 
and repaglinide resulted in an eightfold increase in the area 
under the concentration–time curve (AUC) of repaglinide that 
could prolong its hypoglycemic effect and warn precaution 
while prescribing.18 Therefore, in designing drug-response 
studies, common comorbidities and drug interactions should 
be considered.
Current state of evidence
Metformin
Metformin is the most widely prescribed first-line drug to 
treat T2D. There is a considerable interindividual variability 
in metformin’s glucose-lowering ability with approximately 
one-third of metformin users defined as poor responders.19 The 
mechanism for this variability, and indeed for the mechanism 
of action of metformin, remains uncertain. Metformin is 
also poorly tolerated by some individuals with up to 63% of 
patients experiencing metformin-induced gastrointestinal (GI) 
symptoms leading to 5%–10% premature discontinuation.20
Pharmacokinetics
Metformin is positively charged at physiological pH that 
renders it hydrophilic, resulting in limited passive diffusion. 
Therefore, metformin disposition is dependent on active 
transportation by OCTs (solute carrier family 22 [SLC22]) to 
cross the biological membranes. Plasma membrane monoam-
ine transporter (PMAT), OCT1,21 and OCT3 are involved in 
the apical uptake of metformin into enterocytes (Figure 1). 
In addition, a recent in vitro study identified a possible role 
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of serotonin and choline transporters.22 In the liver, OCT1 
transports metformin to the hepatocytes23 with biliary excre-
tion probably via MATE1.24 In the kidney, OCT2 is highly 
expressed in the basolateral membrane of the distal tubules 
of the kidney facilitating renal uptake,25 whereas MATE1 and 
MATE2, expressed in the apical membrane of the renal epithe-
lial cells, are involved in the renal secretion of metformin.26
Pharmacodynamics
Metformin is believed to lower blood glucose level by 
reducing hepatic glucose production and increasing insulin-
mediated peripheral glucose utilization. Even though the 
molecular mechanisms of how metformin exerts its hypo-
glycemic action are still elusive, it inhibits mitochondrial 
complex I, resulting in decreased adenosine triphosphate 
(ATP), and increased adenosine monophosphate (AMP) 
levels. AMP activates adenosine monophosphate-activated 
protein kinase (AMPK),27 and this had been thought to 
mediate the suppression of gluconeogenesis. However, 
a preserved glucose-lowering effect of metformin has been 
reported in AMPK knockout mice studies.28 Recently, non-
AMPK mechanisms have been proposed. One mechanism 
involves the inhibition of binding of AMP to adenylate 
cyclase by metformin, inhibiting its response to glucagon 
and disrupting downstream cAMP-PKA signaling. This 
inhibits enzymes of the gluconeogenic pathway in favor of 
glycolysis.29 An additional mechanism recently reported sug-
gests that metformin inhibits mitochondrial glycerophosphate 
dehydrogenase enzyme with a subsequent augmentation of 
cytosolic redox state thereby reducing hepatic gluconeogen-
esis.30 Although AMPK is no longer believed to be required 
for glucose lowering, the lipid lowering and any potential 
cancer beneficial effects of metformin are probably mediated 
via this kinase.27
Pharmacogenetics
There is a considerable interindividual variation in metformin 
PK, PD, and adverse effects. The majority of genetic studies 
have focused on variation in the metformin transporters31 
with more recent studies investigating the transcription fac-
tors (TCFs) that regulate these transporters19 and candidate 
genes in metformin PD. While substantial progress has been 
made to understand the detrimental effect of polymorphisms 
in transporter genes on PK, this does not robustly translate 
into drug response with inconsistent results being reported 
across many small studies (Table S1).
OCT1 and metformin efficacy
Nonsynonymous variants in the highly polymorphic SLC22A1 
gene that encodes OCT1 have been reported to affect func-
tionality.32 Studies in healthy and diabetic Caucasians showed 
the association of reduced function variants of OCT1 (G401S, 
R61C, 420del, and G465R) with a higher maximum plasma 
concentration (C
max
) and AUC, lower oral volume of distri-
bution, increased pattern of renal secretary clearance,33 and 
decreased trough steady-state concentration.34
Several studies have been conducted in an effort to link 
OCT1 variants to the clinical efficacy of metformin. In an 
oral glucose tolerance test study carried out in 20 healthy 
volunteers (eight having reference OCT1 and 12 with at 
least one reduced-function OCT1 allele), subjects carrying 
OCT1 variants had a significantly higher (P=0.004) glucose 
AUC compared to those with the reference genotype after 
metformin treatment.35 A study carried out by Christensen 
et al showed individuals carrying the reduced function OCT1 
alleles to have a significantly greater absolute HbA1c reduc-
tion during the initiation as well as maintenance period of 
treatment compared to carriers of the reference genotypes. 
However, the decrease became insignificant when adjusted 
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Figure 1 Transport of metformin by organic cation transporters.
Abbreviations: MATe, multidrug and toxin extrusion antiporter; OCT, organic cation transporter; PMAT, plasma membrane monoamine transporter; Prox. Tub., proximal tubule.
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for baseline HbA1c.34 The Genetics of Diabetes Audit and 
Research Tayside (GoDARTs) is the largest reported study 
to investigate OCT1 variants and glycemic response to 
metformin.36 The GoDARTs investigators studied the two 
most common loss-of-function OCT1 variants, R61C and 
420del in 1,531 T2D patients treated with metformin. They 
showed no effect on a number of outcomes, including HbA1c 
reduction, odds of achieving treatment target, and hazard of 
monotherapy failure. Davis et al also showed no associa-
tion of these variants with absolute change in HbA1c.37 The 
Rotterdam study that investigated eleven tagging single 
nucleotide polymorphisms in SLC22A1 gene could not find 
any significant association with response to metformin.38 The 
Diabetes Prevention Program study evaluated the protective 
role of metformin on the incidence of diabetes in 990 high-
risk participants.39 The major allele of the missense SNP 
in OCT1, rs683369 encoding L160F, showed a significant 
protective effect (HR =0.69, 0.53–0.89, P=0.004). However, 
this variant is not reported to affect OCT1 functionality or 
in linkage disequilibrium (LD) with previously associated 
SNPs.
OCT1 and metformin intolerance: Tarasova et al screened 
the effect of seven variants in genes encoding transporter 
proteins in relation to GI side effects of metformin in 53 
tolerant and 193 intolerant patients.40 Cases were defined as 
those with the presence of at least one of diarrhea, flatulence, 
abdominal pain, asthenia, and vomiting while being treated 
with metformin. Two OCT1 variants, rs628031 (M408V) and 
rs36056065 (8 bp insertion), that are in strong LD showed a 
protective effect (odds ratio [OR] =0.389 [95% confidence 
interval {CI} =0.186–0.815], P=0.012 and OR =0.405 [95% 
CI =0.226–0.724], P=0.002, respectively). In this same study, 
two of the loss-of-function OCT1 variants, rs12208357 
(R61C) and rs34059508 (G465R), showed no significant 
association with intolerance. However, a recent GoDARTs 
study conducted on 2,166 (251 severely intolerant and 1,915 
tolerant) T2D patients showed reduced activity OCT1 vari-
ants (rs12208357 [R61C], rs55918055 [C88R], rs34130495 
[G401S], rs72552763 [M420del], and rs34059508 [G465R]) 
to be important determinants of metformin intolerance.17 
Carriers of two reduced function alleles had 2.4 times higher 
odds (95% CI =1.48–3.93, P=0.001) of developing GI side 
effects. The concomitant use of other drugs known to inhibit 
OCT1 transport increased this risk to an OR of 4 (2.09–8.16, 
P,0.001). In this study, cases were patients who have been on 
immediate release metformin for ,6 months and switched to 
another OHA (including modified release metformin) within 
6 months after stopping the immediate release metformin; 
controls were defined as those patients who were on at least 
2 g of metformin for .6 months.
OCT2: OCT2 is reported to account for ∼80% of 
metformin’s renal clearance.25 Studies in healthy and dia-
betic individuals showed an association of reduced func-
tion OCT2 variants (T199I, T201M, and A270S) with an 
increased plasma concentration and a reduced renal clear-
ance of metformin.41–44 However, other studies showed no 
association.33,45
Studies that aimed to link OCT2 variants with response 
to metformin have been focused on the A270S variant. Most 
of the reported studies do not show any association of this 
variant with response to metformin modeled as a dichoto-
mous trait,42 linear HbA1c reduction,38 or GI side effect.40 
However, a recent study in 209 newly diagnosed patients 
treated with 1,500 mg daily metformin for 1 year showed 
a greater HbA1c reduction (−2.2% vs −1.1%, P,0.05) in 
Chinese diabetic patients who were heterozygous for the 
minor allele than the wild type after adjusting for baseline 
HbA1c, exercise, and diet.43
MATEs: Nonsynonymous MATE1 and MATE2 vari-
ants with a reduced in vitro transport function have been 
reported.46,47 In a study of Chinese patients, homozygous 
carriers of the intronic MATE1 variant (rs2289669 G.A) had 
a greater AUC and a lower clearance (P,0.01) of metformin 
than carriers of the wild type.48 Several studies reported a link 
between this SNP with HbA1c reduction by metformin. Car-
riers of the minor allele at rs2289669 showed a significantly 
greater HbA1c reduction in both the dominant and the reces-
sive models.48–50 In the Diabetes Prevention Program study, 
the T allele of a SNP (rs8065082 C.T) in LD with rs2289669 
(r2=0.8) showed a protective effect against the incidence of 
diabetes in high-risk individuals.39 Finally, rs12943590, a 
promoter variant for MATE2, has been associated with PK of 
metformin in healthy individuals.51 This difference has also 
been seen in HbA1c reduction37 and successfully replicated 
in another study.47
In conclusion, while a number of variants have been 
reported in the metformin transporter genes, on the whole, 
there have been no definitive signals for these variants on 
glycemic response to metformin. However, MATE1 and 
MATE2 variants show some promise and larger studies, or 
meta-analysis of existing studies, are required to establish 
how much of these results are biased by small sample size 
and publication bias.
Gene–gene interaction: Although variants in transporter 
genes showed an association with metformin response, 
individual variants explain only a small fraction of the 
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variation. Given that multiple transporters are involved in the 
disposition of metformin and localization of uptake and efflux 
transporters in the same organ (Figure 1), joint investigation 
could give a better understanding. Interaction between the 
OCT2 variant, c.808 G.T (rs316019), and MATE1 variant, 
g.−66 T.C (rs2252281), in relation to the PK of metformin 
was reported by Christensen et al.45 The c.808 G.T alone 
showed no effect on either secretory or renal clearance of 
metformin. However, an increased clearance was observed 
with carriers of the c.808 G.T variant that are homozy-
gous for g.−66 T.C. In the Rotterdam study, interaction 
between the intronic MATE1 and OCT1 SNPs, rs2289669 
and rs622342, respectively, was investigated. A more pro-
nounced glucose-lowering effect of rs2289669 in MATE1 
was reported in metformin users with CC genotype than AA 
genotype for OCT1.52 Gene–gene interaction between g.−66 
T.C/rs2252281 and g.−130 G.A/rs12943590 promotor 
variants of MATE1 and MATE2, respectively, was reported 
by Stocker et al.51 Carriers of both variants showed a greater 
renal and secretary clearance. This clearly signifies the role 
of gene–gene interaction and the importance of complex 
network/pathway analysis to better understand the PK and 
PD of metformin.
TCF variants: Rather than studying transporter vari-
ants per se, an elegant study explored variants in TCFs 
that potentially regulate the expression of these transporter 
genes.19 They studied variants in specificity protein (SP) 1, 
which regulates the expression of a number of these trans-
porter genes; activating enhancer-binding protein 2, which 
represses MATE1 expression; and the TCFs, hepatocyte 
nuclear factor 4, alpha (HNF4α) and peroxisome proliferator-
activated, alpha (PPARα). They reported five variants in or 
near SP1 and one variant in activating enhancer-binding 
protein 2 that showed association with metformin elimina-
tion and HbA1c change. Of these, those homozygous GG 
at rs784892 (intronic SNP of AMHR2, downstream gene to 
SP1) achieved a 1.1% lower HbA1c and 98 mL/min lower 
secretory clearance of metformin than AA homozygotes. Up 
to 24% reduction in apparent clearance was also reported in 
patients’ homozygous GG at rs784888, a downstream vari-
ant to SP1. This SNP was associated with HbA1c reduction 
with β coefficient of −0.36% per G allele (P=0.01 before 
Bonferroni correction). Variants in HNF4α and PPARα were 
associated with HbA1c reduction, but their effect could not 
be explained by the PK of metformin suggesting that further 
investigation of other mechanisms is required.
Polymorphisms in the PD pathway: Genetic variants 
affecting the PD of metformin are not well studied. There 
are few candidate gene studies that reported nominal 
associations with metformin efficacy (Table S1). The GWAS 
on metformin response in 1,024 T2D incident users revealed 
an association of rs11212617, a SNP near ATM gene, with 
glycemic response to metformin as a linear reduction in 
glycated hemoglobin or achieving treatment target (HbA1C 
,7%).8 This finding was further replicated in two indepen-
dent cohorts from Scotland and the UK with sample sizes of 
1,783 and 1,113, respectively.53 A meta-analysis of three other 
studies separately or in combination with previous bigger 
studies confirmed the association of the variant with treat-
ment success.53 This finding was also replicated in a Chinese 
population.54 However, the Diabetes Prevention Program 
could not find any effect of rs11212617 on the efficacy of 
metformin in delaying progression to diabetes.55
Sulfonylureas
SUs were first introduced into clinical practice in the 1950s 
and have long been a cornerstone of treatment in T2D. Cur-
rently, they are used as the first-line agents or an add-on 
therapy to other OHAs, usually metformin. About a quarter 
of newly diagnosed patients initiate therapy with SUs.56 Each 
drug in the group varies in their PK parameters, insulin secre-
tory potency, and onset and duration of action.
PK and PD
The polymorphic CYP2C9 isoenzyme catalyzes the biotrans-
formation of SUs in the liver. Catalytic function of the 
enzyme is reported to be affected by the type of inherited 
amino acid substitution.57 Substitution of arginine with 
cysteine at amino acid position 144 (Arg144Cys) and iso-
leucine with leucine at position 359 (Ile359Leu) gives rise to 
mutant alleles, CYP2C9*2 and CYP2C9*3, respectively. The 
mutant alleles are known to have a reduced catalytic activity 
than the wild-type CYP2C9*1. Involvement of CYP2C19 in 
the metabolism of SUs is also reported.58 CYP2C19*2 (681 
G.A) and CYP2C19*3 (636 G.A) are variants that encode 
a nonfunctional CYP2C19 enzyme. Individuals with either of 
the variants are labeled as poor metabolizers.58 The *3 variant 
is most common in Asians with a frequency of 10%–25% 
compared to that of 2%–6% in Caucasians.
SUs induce glucose-independent insulin release from the 
pancreatic β-cells by binding to the ATP-sensitive potassium 
(K
ATP
) channel (Figure 2).59 The channel is composed of four 
subunits of the SU receptor (SUR) 1 and four subunits of 
the potassium inward rectifier channel (Kir) 6.2. Two SU-
binding sites have been reported in the channel. The A site 
resides exclusively on the SUR1 and the B site is available 
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on both subunits of the K
ATP
 channel. Binding of SUs to these 
receptors induces the closure of K
ATP
 channels and increases 
intracellular K+ ion and hence membrane depolarization 
with subsequent opening of voltage-gated Ca2+ channels 
that increase intracellular Ca2+ followed by the release of 
insulin-containing granules.
Pharmacogenetics
Interindividual variability in SU response exists. Follow-
ing SU initiation, an estimated 10%–20% of patients will 
have ,20 mg/dL FPG reduction.20 Clinical factors, such as 
baseline glucose, duration of diabetes, β-cell function, and 
degree of insulin resistance, affect response to SUs.20 Variants 
in genes encoding proteins involved in the PK and PD are 
widely reported to influence therapeutic outcome of SUs.
CYPs: Several studies investigated the effect of mutant 
alleles of the rate-limiting CYP2C9 on the PK and PD and 
the safety of SUs in healthy and T2D individuals. Reduced 
drug-metabolizing activity has been reported in individuals 
carrying either the CYP2C9*2 or the CYP2C9*3 variants, 
*3 being more profound.60 Compared to wild-type carri-
ers, healthy male volunteers homozygous for CYP2C9*3 
and CYP2C9*2 had a 50% and 10% lower oral clearance 
of glyburide, respectively.61 In line with this, a significant 
increase in AUC and plasma half-life (t
1/2
) of glyburide has 
been reported for heterozygous CYP2C9*3 than *1/*1 car-
riers.62 Similar result was also reported for tolbutamide.63 
The impact of CYP2C9 on the PK of the second generation 
SUs was also studied. Wang et al reported 40% and 30% 
more mean AUC of glimepiride for *3/*3 and *3/*1 carriers, 
respectively, compared to the wild type.64
Reduced function CYP2C19 variants also influence 
metabolism of SUs. More than threefold increase in AUC 
and prolonged half-life of gliclazide were reported among 
male healthy Chinese volunteers with reduced CYP2C19 
variants compared to carriers of the wild type.65
Influence of CYP variants on efficacy to SUs has been 
widely studied. The largest study based on retrospective data 
on 1,073 incident users of SUs from the GoDARTs showed that 
carriers of loss-of-function CYP2C9*2 or CYP2C9*3 
alleles were 3.4-fold more likely to achieve therapeutic 
target than carriers of the wild type, resulting in 0.5% 
greater HbA1c reduction.66 In the Rotterdam study, Becker 
et al defined response in terms of maintenance dose 
achieved among the incident SU users.67 In a subgroup of 
172 patients who were on tolbutamide, a lower dose was needed 
to regulate glucose in the carriers of CYP2C9*3 than in the 
carriers of the wild type. A reduction in HbA1c in carriers of 
CYP2C9*1/*3 was also reported among Japanese patients who 
have been on glimepiride.68 These consistent findings are some 
of the most robust pharmacogenetic findings in the diabetes field 
and could potentially translate into genotype-guided therapy in 
SUs. However, prospective studies in T2D patients are required 
before translating into clinical practice. The role that CYP2C19 
could play in the metabolism of gliclazide is documented.58 How-
ever, studies to link this with glycemic response are lacking.
Polymorphisms in mechanistic targets
Following the identification of SU-binding sites SUR1 and 
Kir6.2 (encoded by ABCC8 and KCNJ11, respectively), 
variants in these genes have been the subjects of many 
pharmacogenetic investigations. Rare pathogenic mutations 
in these genes lead to neonatal monogenic diabetes.69 Due to 
the low levels of insulin and ketoacidosis, insulin has been the 
typical treatment in neonatal diabetes. Successful transition 
from long-term insulin to SU treatment has been reported by 
Pearson et al in 2006.70 Following this, a number of studies 
investigated two strongly linked nonsynonymous common 
variants in the ABCC8 (S1369A, rs757110) and KCNJ11 
(E23K, rs5219) in patients with T2D.
ABCC8/KCNJ11: The E23K and S1369A variants form 
a haplotype. While K
ATP
 channels containing the K23/A1369 
haplotype are more sensitive to inhibition by gliclazide, 
they are less sensitive to inhibition by tolbutamide, chlo-
rpropamide, and glimepiride.71 Association of S1369A with 
glycemic control in 115 Chinese patients who have been on 
gliclazide for 8 weeks was reported.72 Carriers of minor allele 
had a greater HbA1c reduction than carriers of the wild type 
(1.60%±1.36% vs 0.76%±1.70%, P=0.04). Another larger 
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Figure 2 Action of sulfonylureas on β-cells.
Abbreviations: SUs, sulfonylureas; SUR1, sulfonylurea receptor 1.
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study also showed an association of the minor allele with a 
greater reduction in fasting (P,0.001) and 2-hour (P,0.003) 
glucose levels.73 Association between the KCNJ11 E23K and 
efficacy to SUs was reported in Chinese patients by Li et al.74 
In this study, 108 newly diagnosed T2D individuals have been 
treated with gliclazide MR for 16 weeks. Homozygous KK 
carriers had a lower FPG and were more likely to achieve 
the target FPG of 7.0 mmol/L (Plog rank =0.03) than E allele 
carriers. In another study carried out in 101 T2D Caucasians 
treated with SUs after metformin therapy, homozygous 
KK carriers showed a greater HbA1c reduction than EE 
homozygous after 6 months of therapy (1.04%±0.10% vs 
0.79%±0.12%, P=0.04).75
However, other studies could not replicate the above 
findings. The UK Prospective Diabetes Study investigated 
response to SUs in 363 individuals based on FPG measured at 
two time points in a 1-year period.76 No significant association 
between E23K and FPG was observed. This finding could 
probably be confounded by continual dose adjustment carried 
out in the UK Prospective Diabetes Study. In a study con-
ducted on 525 Caucasians who have been on glibenclamide 
and metformin, carriers of the K allele showed 1.69 ([95% CI 
=1.02–2.74], P=0.04) times higher odds of secondary treat-
ment failure, defined as FPG .300 mg/dL (16.7 mmol/L), 
than those who were homozygous for the reference allele.77 
Since metformin was used as an add-on therapy, the failure 
is for the combination rather than SU alone. Moreover, this 
secondary failure phenotype is more likely to reflect diabetes 
progression associated with the K allele than SU response. 
Another study carried out in 176 (92 experienced hypogly-
cemia and 84 not) T2D patients showed no association of 
the E23K variant with a mild hypoglycemia.78 This study 
might be confounded by an incomplete definition of mild 
hypoglycemia as it relies on patients’ self-report.
TCF7L2: TCF7L2 harbors the strongest T2D risk variants 
among the 120 GWAS-established loci. It encodes T-cell TCF4, 
an important downstream target of the WNT signaling pathway.79 
Reduced insulin secretion has been reported in relation to two 
intronic variants, rs7903146 and rs12255372, in the TCF7L2 
gene and hence hypothesized to affect SU response.80
GoDARTs is the largest study conducted on 901 Scot-
tish patients to link TCF7L2 variants with SU response.81 
Patients homozygous for the minor allele of rs12255372 
G.T were nearly twofold less likely to achieve therapeutic 
target after 3–12 months of SU treatment than homozygous 
carriers of the reference allele. Similar result was reported 
for rs7903146. Three other independent groups also showed 
a consistent result (Table S2).82–84
In conclusion, notable findings have been reported in 
the pharmacogenetics of SUs. Robust associations between 
variants in the CYP2C9, ABBC8/KCNJ11 and TCF7L2, are 
reported. More comprehensive assessments of these associa-
tions will be necessary to translate this genetic information 
into clinical utility.
Meglitinides
Meglitinides (glinides) are short acting non-SU secretagogues 
that lower postprandial glucose excursions preferentially 
by stimulating early phase insulin secretion. They act by 
regulating potassium channels in the pancreatic β-cells via 
a distinct mechanism from that of SUs. They are not com-
monly used in the UK.
After oral administration, glinides are absorbed rapidly with 
the peak plasma drug levels reached within 1 hour. Organic 
anion transporting polypeptide 1B1 (OATP1B1), encoded by 
Solute Carrier Organic Anion Transporter Family, Member 
1B1 (SLCO1B1), mediates their transport into the liver,85 
where .95% of the oral dose get metabolized by the CYP 
family isozymes.57
Association of genetic variants in the SLCO1B1, CYP2C9, 
and CYP2C8 genes with the PK and/or efficacy of glinides has 
been reported. In healthy individuals, carriers of the variant 
allele c.521 T.C in the SLCO1B1 had a reduced transport 
and an increased plasma concentration of repaglinide and 
nateglinide.86–89 The *1B/*1B haplotype in the same gene was 
also associated with a reduced transport of glinides.90 Associa-
tion of the *3 variant in CYP2C8 and CYP2C9 with the PK of 
nateglinide and repaglinide has also been reported.86,91,92
In a study carried out in 100 Chinese patients, He et al 
investigated the effect of KCNJ11 genotype on the efficacy 
of repaglinide after 24 weeks of treatment.93 Carriers of the 
K allele of E23K showed a greater HbA1c reduction (EE: 
1.52%±1.03%, EK: 2.33%±1.53%, and KK: 2.65%±1.73%, 
P=0.02). However, this result could be confounded by base-
line effect as carriers of the variant allele had higher HbA1c 
at baseline than carriers of the wild type.
Studies pertaining to the pharmacogenetics of glinides 
are confounded by small sample sizes (most of them ,100). 
PD investigations are available for repaglinide only, and most 
of the PK studies are limited to healthy volunteers (Table S3). 
Therefore, further studies with bigger sample sizes, meth-
odological diversities, and replication are required.
Thiazolidinediones
TZDs, also known as glitazones, are OHAs that act as insulin 
sensitizers in different tissues, including the liver, muscle, and 
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adipose tissue. Glitazones act via the activation of PPAR-γ 
that regulates the transcription of multiple downstream genes 
involved in glucose and lipid metabolism. They reduce HbA1c 
by ∼0.5%–1.4%.94 There are three glitazones that have been 
licensed: rosiglitazone, pioglitazone, and troglitazone. While 
troglitazone was withdrawn from the global market in 2000 
due to idiosyncratic hepatotoxicity, marketing authorization 
for roziglitazone has been withdrawn in Europe and put under 
restrictions in the USA due to the potential cardiovascular 
risks. France and Germany have suspended pioglitazone due 
to an increased risk of bladder cancer. However, recent mul-
tipopulation studies showed no association of pioglitazone or 
rosiglitazone with the risk of bladder cancer.95,96
Pharmacogenetics
CYP2C8 and SLCO1B1: Hepatic uptake of TZDs is medi-
ated by OAT1B197 with metabolism mostly by CYP2C8. 
Genetic variants in genes encoding these proteins have been 
investigated for their possible impact on the PK of TZDs in 
healthy volunteers. The homozygote carriers of CYP2C8*3 
had 36% lower rosiglitazone plasma concentration and 39% 
higher weight-adjusted oral clearance compared to carriers 
of the wild type.98,99 Similar trends have been reported for 
pioglitazone in two other studies.100,101 For SLCO1B1, despite 
in silico modeling, PK studies in healthy Caucasians found 
no association between loss-of-function 521 T.C variant 
of SLCO1B1 and plasma concentrations of rosiglitazone 
and pioglitazone.99,102 It is worth noting that these studies 
had small samples that could limit statistical power to detect 
moderate genetic effects.
PPARG: PPARG, the mechanistic target of TZDs, is 
an obvious candidate for pharmacogenetic investigations. 
Association of the common variant rs1801282 P12A with 
risk of T2D has been reported.103 The most robust study that 
showed an association between P12A and response to pio-
glitazone was carried out in 250 Chinese patients.104 Carriers 
of the minor allele (Ala) showed 2.32 ([95% CI =1.10–4.87], 
P=0.03) times higher odds of being a responder than carriers 
of the wild type. In this study, responders were defined 
as those with .15% decrease in HbA1c levels or .20% 
decrease in FPG levels (or both) after 24 weeks of pioglita-
zone treatment. Association of the same variant with a linear 
reduction in HbA1c and FPG after pioglitazone therapy was 
replicated in an independent cohort of 67 patients.105 Similar 
trend has been reported in 198 Korean patients treated with 
4 mg rosiglitazone daily for 3 months.106
Adverse outcomes: Adverse effects induced by TZD 
therapy have been investigated in relation to genetic variants. 
Watanabe et al studied association of troglitazone-induced 
hepatotoxicity with the 68 polymorphic sites of 51 candidate 
genes in 110 Japanese patients (25 cases and 85 controls).10 
The strongest correlation was observed for combined null 
genotype of glutathione S-transferase theta-1 and glutathione 
S-transferase mu-1 (OR =3.7 [95% CI =1.4–10.1], P=0.008). 
In another Japanese study, association of troglitazone-induced 
liver injury with mutations in CYP2C19 was reported.11 In the 
Diabetes REduction Assessment with ramipril and rosiglita-
zone Medication (DREAM) trial, a higher rate of roziglitazone-
induced edema (OR =1.89 [95% CI =1.47–2.42], P=0.017) 
was reported for patients’ homozygous CC for rs6123045, a 
variant at the Nuclear Factor of Activated T-cells, Cytoplasmic, 
Calcineurin-Dependent 2 (NFATC2) locus (Table S4).107
incretins
There is a greater insulin secretory response to oral than intra-
venous glucose load despite the same glucose concentrations 
at the level of the β-cell; this is termed as the incretin effect and 
has been attributed to the incretin peptides: GLP-1 and gastric 
inhibitory polypeptide.108 GLP-1 is a glucoincretin hormone 
secreted from enteroendocrine L cells within the crypts of 
the intestinal mucosa. It has a t
1/2
 of 1–2 minutes due to rapid 
degradation by the enzyme DPP-4 and thus limited therapeutic 
potential.109 Two therapeutic strategies were developed to over-
come this rapid degradation – oral agents that inhibit DPP-4 
(known as gliptins) and injectable agents that are resistant to 
breakdown by DPP-4 (GLP-1R agonists).
Pharmacogenetic studies on GLP-1R agonists are limited. 
A pilot study on healthy Caucasians showed differences in the 
insulinotropic response to exogenous GLP-1 in relation to two 
common variants (rs6923761 G.A and rs3765467 C.T) in 
the GLP-1R gene.110 ’t Hart et al reported significant association 
between a variant near the Chymotrypsinogen B1/2 (CTRB1/2) 
gene (rs7202877) and glycemic response to gliptins. CTRB1/2 
encodes chymotrypsin, and the G allele at rs7202877 variant 
was associated with an increased fecal chymotrypsin activity. 
Carriers of the G allele at this SNP showed 0.51%±0.16% lower 
HbA1c reduction compared to TT genotype (P=0.0015) after 
being on gliptins for at least 3 months.111 Association of vari-
ants in other T2D-related genes, such as Potassium Channel, 
Voltage Gated KQT-Like Subfamily Q, Member 1 (KCNQ1), 
TCF7L2, and Wolfram Syndrome 1 (WFS1), with GLP-1R 
agonist response has also been reported (Table S5).
SGLT-2 inhibitors
SGLT-2 inhibitors are a new class of OHAs that 
inhibit SGLT-2-mediated renal reabsorption of glucose 
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thereby increase glycosuria, resulting in a reduction of 
hyperglycemia independent of β-cell function.112 After oral 
administration, SGLT-2 inhibitors show a bioavailability of 
65%–78% with a t
1/2
 ranging 10–13 hours allowing once a 
day administration.112 They are mainly eliminated through 
O-glucuronidation by uridine diphosphate glucuronosyl-
transferases (UGTs).113 A recent study carried out in 134 
healthy and T2D subjects showed involvement of UGT1A9 
and UGT2B4 in the metabolism of canagliflozin.113 Carriers 
of reduced function variants, UGT1A9*3 and UGT2B4*2, 
had an increased plasma concentration of canagliflozin than 
carriers of the parent allele.
SGLT-2 inhibitors reduce HbA1c by 0.58%–1% when 
used as a mono- or an add-on therapy.114 Individual variation 
in response to SGLT-2 inhibitors has been reported, and part 
of this variation could be attributable to genetic variation. 
Nonsense and missense mutations in the SLC2A5 gene that 
result in the loss of SGLT-2 function cause familial renal 
glycosuria and are associated with the reduced circulating 
glucose levels.115,116
Conclusion and future directions
More than 120 studies pertaining gene–drug interaction 
in diabetes have been investigated for this review (Tables 
S1–S5). Even though small studies that lack replication 
predominate, well-powered, and successfully replicated 
findings are emerging. Promising advances in the phar-
macogenomics of T2D have already been made. Genetic-
guided therapy is now mainstream in the case of maturity 
onset diabetes of the young and neonatal diabetes.70,117 To 
further translate pharmacogenomics research into clinical 
practice, more well-designed studies with sufficiently large 
sample size and well-characterized phenotype should be 
conducted, and where possible meta-analysis across studies 
should be undertaken to provide robust evidence for an asso-
ciation. In addition, data from high-throughput sequencing 
of rare variants, noncoding regions, and multilevel -omics, 
including transcriptomics, proteomics, metabolomics, and 
metagenomics, may yield greater mechanistic insights and 
possibly biomarkers with a larger clinical effect.
Disclosure
The authors report no conflicts of interest in this work.
References
1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of 
diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.
2. International Diabetes Federation (IDF). IDF Diabetes Atlas. 6th ed. 
Brussels: International Diabetes Federation; 2013.
 3. Casagrande SS, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The preva-
lence of meeting A1C, blood pressure, and LDL goals among people 
with diabetes, 1988-2010. Diabetes Care. 2013;36(8):2271–2279.
 4. Becker ML, Pearson ER, Tká  I. Pharmacogenetics of oral antidiabetic 
drugs. Int J Endocrinol. 2013;2013:686315.
 5. DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship 
of baseline HbA1c and efficacy of current glucose-lowering thera-
pies: a meta-analysis of randomized clinical trials. Diabetic Med. 
2010;27(3):309–317.
 6. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonad-
herence on hospitalization and mortality among patients with diabetes 
mellitus. Arch Intern Med. 2006;166(17):1836–1841.
 7. Zhou K, Donnelly L, Yang J, et al. Heritability of variation in glycaemic 
response to metformin: a genome-wide complex trait analysis. Lancet 
Diabetes Endocrinol. 2014;2(6):481–487.
 8. Zhou K, Bellenguez C, Spencer CC, et al. Common variants near ATM 
are associated with glycemic response to metformin in type 2 diabetes. 
Nat Genet. 2011;43(2):117–120.
 9. Vella A. Pharmacogenetics for type 2 diabetes: practical considerations 
for study design. J Diabetes Sci Technol. 2009;3(4):705–709.
 10. Watanabe I, Tomita A, Shimizu M, et al. A study to survey susceptible 
genetic factors responsible for troglitazone-associated hepatotoxicity in 
Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 
2003;73(5):435–455.
 11. Kumashiro R, Kubota T, Koga Y, et al. Association of troglitazone-
induced liver injury with mutation of the cytochrome P450 2C19 gene. 
Hepatol Res. 2003;26(4):337–342.
 12. Donnelly LA, Doney AS, Hattersley AT, Morris AD, Pearson ER. The 
effect of obesity on glycaemic response to metformin or sulphonylureas 
in Type 2 diabetes. Diabet Med. 2006;23(2):128–133.
 13. Ong CR, Molyneaux LM, Constantino MI, Twigg SM, Yue DK. Long-
term efficacy of metformin therapy in nonobese individuals with type 
2 diabetes. Diabetes Care. 2006;29(11):2361–2364.
 14. Miyazaki Y, De Filippis E, Bajaj M, Wajcberg E, Glass LC, Triplitt C. 
Predictors of improved glycemic control with rosiglitazone therapy 
in type 2 diabetic patients: a practical approach for the primary care 
physician. Br J Diabetes Vasc Dis. 2005;5:28–35.
 15. Kim YM, Cha BS, Kim DJ, et al. Predictive clinical parameters for 
therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus. 
Diabetes Res Clin Pract. 2005;67:43–52.
 16. Scheen AJ. Drug interactions of clinical importance with antihyperg-
lycaemic agents: an update. Drug Saf. 2005;28(7):601–631.
 17. Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CN, Pearson ER. 
Association of organic cation transporter 1 with intolerance to metformin 
in type 2 diabetes: a GoDARTS Study. Diabetes. 2015;64(5):1786–1793.
 18. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gem-
fibrozil, itraconazole, and their combination on the pharmacokinet-
ics and pharmacodynamics of repaglinide: potentially hazardous 
interaction between gemfibrozil and repaglinide. Diabetologia. 
2003;46:347–351.
 19. Goswami S, Yee SW, Stocker S, et al. Genetic variants in transcription 
factors are associated with the pharmacokinetics and pharmacodynam-
ics of metformin. Clin Pharmacol Ther. 2014;96(3):370–379.
 20. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann 
Intern Med. 1999;131(4):281–303.
 21. Han TH, Everett RS, Proctor WR, et al. Organic cation transporter 
1 (OCT1/mOct1) is localized in the apical membrane of Caco-2 cell 
monolayers and enterocytes. Mol Pharmacol. 2013;84(2):182–189.
 22. Han TK, Proctor WR, Costales CL, Cai H, Everett RS, Thakker DR. Four 
cation-selective transporters contribute to apical uptake and accumula-
tion of metformin in Caco-2 cell monolayers. J Pharmacol Exp Ther. 
2015;352(3):519–528.
 23. Müller J, Lips KS, Metzner L, Neubert RH, Koepsell H, Brandsch M. Drug 
specificity and intestinal membrane localization of human organic cation 
transporters (OCT). Biochem Pharmacol. 2005;70(12):1851–1860.
 24. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of 
metformin. Clin Pharmacokinet. 2011;50(2):81–98.
Pharmacogenomics and Personalized Medicine 2016: 9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
27
A review on pharmacogenetics in type 2 diabetes
 25. Kimura N, Masuda S, Tanihara Y, et al. Metformin is a superior 
substrate for renal organic cation transporter OCT2 rather 
than hepatic OCT1. Drug Metab Pharmacokinet. 2005;20(5): 
379–386.
 26. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, 
Moriyama Y. A human transporter protein that mediates the final 
excretion step for toxic organic cations. Proc Natl Acad Sci USA. 
2005;102(50):17923–17928.
 27. Pernicova I, Korbonits M. Metformin – mode of action and 
clinical implications for diabetes and cancer. Nat Rev Endocrinol. 
2014;10(3):143–156.
 28. Foretz M, Hébrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeo-
genesis in mice independently of the LKB1/AMPK pathway via a decrease 
in hepatic energy state. J Clin Invest. 2010;120(7):2355–2369.
 29. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides 
suppress hepatic glucagon signalling by decreasing production of cyclic 
AMP. Nature. 2013;494(7436):256–260.
 30. Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses 
gluconeogenesis by inhibiting mitochondrial glycerophosphate dehy-
drogenase. Nature. 2014;510(7506):542–546.
 31. Maruthur NM, Gribble MO, Bennett WL, et al. The pharmaco-
genetics of type 2 diabetes: a systematic review. Diabetes Care. 
2014;37:876–886.
 32. Nies AT, Koepsell H, Damme K, Schwab M. Organic cation 
transporters (OCTs, MATEs), in vitro and in vivo evidence for the 
importance in drug therapy. Handb Exp Pharmacol. 2011;(201): 
105–167.
 33. Tzvetkov MV, Vormfelde SV, Balen D, et al. The effects of genetic 
polymorphisms in the organic cation transporters OCT1, OCT2, and 
OCT3 on the renal clearance of metformin. Clin Pharmacol Ther. 
2009;86(3):299–306.
 34. Christensen MM, Brasch-Andersen C, Green H, et al. The pharmaco-
genetics of metformin and its impact on plasma metformin steady-state 
levels and glycosylated hemoglobin A1c. Pharmacogenet Genom-
ics. 2011;21(12):837–850. [Erratum in Pharmacogenet Genomics. 
2015;25(1):48–50].
 35. Shu Y, Brown C, Castro RA, et al. Effect of genetic variation in the 
organic cation transporter 1, OCT1, on metformin pharmacokinetics. 
Clin Pharmacol Ther. 2008;83(2):273–280.
 36. Zhou K, Donnelly LA, Kimber CH, et al. Reduced-function 
SLC22A1 polymorphisms encoding organic cation transporter 1 
and glycemic response to metformin: a GoDARTs study. Diabetes. 
2009;58(6):1434–1439.
 37. Davis R, Giacomini K, Yee SW, Jenkins G, McCarty CA, Wilke RA. 
PS1-10: response to metformin and genetic variants of organic cat-
ion and multidrug and toxin extrusion transporters. Clin Med Res. 
2010;8(3–4):191.
 38. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, 
Stricker BH. Genetic variation in the organic cation transporter 1 is 
associated with metformin response in patients with diabetes mellitus. 
Pharmacogenomics J. 2009;9(4):242–247.
 39. Jablonski KA, McAteer JB, de Bakker PI, et al; Diabetes Prevention 
Program Research Group. Common variants in 40 genes assessed 
for diabetes incidence and response to metformin and lifestyle inter-
vention in the diabetes prevention program. Diabetes. 2010;59(10): 
2672–2681.
 40. Tarasova L, Kalnina I, Geldnere K, et al. Association of genetic varia-
tion in the organic cation transporters OCT1, OCT2 and multidrug and 
toxin extrusion 1 transporter protein genes with the gastrointestinal side 
effects and lower BMI in metformin-treated type 2 diabetes patients. 
Pharmacogenet Genomics. 2012;22(9):659–666.
 41. Song IS, Shin HJ, Shim EJ, et al. Genetic variants of the organic cation 
transporter 2 influence the disposition of metformin. Clin Pharmacol 
Ther. 2008;84(5):559–562.
 42. Shikata E, Yamamoto R, Takane H, et al. Human organic cation trans-
porter (OCT1 and OCT2) gene polymorphisms and therapeutic effects 
of metformin. J Hum Genet. 2007;52(2):117–122.
 43. Hou W, Zhang D, Lu W, et al. Polymorphism of organic cation 
transporter 2 improves glucose-lowering effect of metformin via influ-
encing its pharmacokinetics in Chinese type 2 diabetic patients. Mol 
Diagn Ther. 2015;19(1):25–33.
 44. Chen Y, Li S, Brown C, et al. Effect of genetic variation in the organic 
cation transporter 2 on the renal elimination of metformin. Pharmaco-
genet Genomics. 2009;19(7):497–504.
 45. Christensen MM, Pedersen RS, Stage TB, et al. A gene-gene interac-
tion between polymorphisms in the OCT2 and MATE1 genes influ-
ences the renal clearance of metformin. Pharmacogenet Genomics. 
2013;23(10):526–534.
 46. Kajiwara M, Terada T, Ogasawara K, et al. Identification of multidrug 
and toxin extrusion (MATE1 and MATE2-K) variants with complete 
loss of transport activity. J Hum Genet. 2009;54(1):40–46.
 47. Choi JH, Yee SW, Ramirez AH, et al. A common 5’-UTR variant in 
MATE2-K is associated with poor response to metformin. Clin Phar-
macol Ther. 2011;90(5):674–684.
 48. He R, Zhang D, Lu W, et al. SLC47A1 gene rs2289669 G.A variants 
enhance the glucose-lowering effect of metformin via delaying its 
excretion in Chinese type 2 diabetes patients. Diabetes Res Clin Pract. 
2015;109(1):57–63.
 49. Tká  I, Klim áková L, Javorský M, et al. Pharmacogenomic associa-
tion between a variant in SLC47A1 gene and therapeutic response to 
metformin in type 2 diabetes. Diabetes Obes Metab. 2013;15(2): 
189–191.
 50. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, 
Stricker BH. Genetic variation in the multidrug and toxin extru-
sion 1 transporter protein influences the glucose-lowering effect of 
metformin in patients with diabetes: a preliminary study. Diabetes. 
2009;58(3):745–749.
 51. Stocker SL, Morrissey KM, Yee SW, et al. The effect of novel pro-
moter variants in MATE1 and MATE2 on the pharmacokinetics and 
pharmacodynamics of metformin. Clin Pharmacol Ther. 2013;93(2): 
186–194.
 52. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, 
Stricker BH. Interaction between polymorphisms in the OCT1 and 
MATE1 transporter and metformin response. Pharmacogenet Genom-
ics. 2010;20(1):38–44.
 53. van Leeuwen N, Nijpels G, Becker ML, et al. A gene variant near ATM 
is significantly associated with metformin treatment response in type 2 
diabetes: a replication and meta-analysis of five cohorts. Diabetologia. 
2012;55(7):1971–1977.
 54. Zhou Y, Guo Y, Ye W, et al. rs11212617 is associated with metformin 
treatment response in type 2 diabetes in Shanghai local Chinese popula-
tion. Int J Clin Pract. 2014;68(12):1462–1466.
 55. Florez JC, Jablonski KA, Taylor A, et al; Diabetes Prevention Program 
Research Group. The C allele of ATM rs11212617 does not associate 
with metformin response in the diabetes prevention program. Diabetes 
Care. 2012;35(9):1864–1867.
 56. Desai NR, Shrank WH, Fischer MA, et al. Patterns of medication initia-
tion in newly diagnosed diabetes mellitus: quality and cost implications. 
Am J Med. 2012;125(3):302.e1–302.e7.
 57. Kirchheiner J, Roots I, Goldammer M, et al. Effect of genetic poly-
morphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the 
pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin 
Pharmacokinet. 2005;44(12):1209–1225.
 58. Xu H, Murray M, McLachlan AJ. Influence of genetic polymorphisms 
on the pharmacokinetics and pharmacodynamics of sulfonylurea drugs. 
Curr Drug Metab. 2009;10:643–658.
 59. Shyng S, Nichols CG. Octameric stoichiometry of the KATP channel 
complex. J Gen Physiol. 1997;110(6):655–664.
 60. Goldstein JA. Clinical relevance of genetic polymorphisms in the human 
CYP2C subfamily. Br J Clin Pharmacol. 2001;52(4):349–355.
 61. Kirchheiner J, Brockmöller J, Meineke I, et al. Impact of CYP2C9 
amino acid polymorphisms on glyburide kinetics and on the insulin 
and glucose response in healthy volunteers. Clin Pharmacol Ther. 
2002;71(4):286–296.
Pharmacogenomics and Personalized Medicine 2016: 9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
28
Dawed et al
 62. Yin OQ, Tomlinson B, Chow MS. CYP2C9, but not CYP2C19, 
polymorphisms affect the pharmacokinetics and pharmacodynamics 
of glyburide in Chinese subjects. Clin Pharmacol Ther. 2005;78(4): 
370–377.
 63. Shon JH, Yoon YR, Kim KA, et al. Effects of CYP2C19 and CYP2C9 
genetic polymorphisms on the disposition of and blood glucose 
lowering response to tolbutamide in humans. Pharmacogenetics. 
2002;12(2):111–119.
 64. Wang R, Chen K, Wen SY, Li J, Wang SQ. Pharmacokinetics of 
glimepiride and cytochrome P450 2C9 genetic polymorphisms. Clin 
Pharmacol Ther. 2005;78(1):90–92.
 65. Zhang Y, Si D, Chen X, et al. Influence of CYP2C9 and CYP2C19 
genetic polymorphisms on pharmacokinetics of gliclazide MR in 
Chinese subjects. Br J Clin Pharmacol. 2007;64(1):67–74.
 66. Zhou K, Donnelly L, Burch L, et al. Loss-of-function CYP2C9 vari-
ants improve therapeutic response to sulfonylureas in type 2 diabetes: 
a Go-DARTS study. Clin Pharmacol Ther. 2010;87(1):52–56.
 67. Becker ML, Visser LE, Trienekens PH, Hofman A, van Schaik RH, 
Stricker BH. Cytochrome P450 2C9 *2 and *3 polymorphisms and 
the dose and effect of sulfonylurea in type II diabetes mellitus. Clin 
Pharmacol Ther. 2008;83(2):288–292.
 68. Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M. 
Effect of CYP2C9 genetic polymorphisms on the efficacy and phar-
macokinetics of glimepiride in subjects with type 2 diabetes. Diabetes 
Res Clin Pract. 2006;72(2):148–154.
 69. Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neona-
tal diabetes: new clinical syndromes, new scientific insights, and new 
therapy. Diabetes. 2005;54(9):2503–2513.
 70. Pearson ER, Flechtner I, Njølstad PR, et al; Neonatal Diabetes Inter-
national Collaborative Group. Switching from insulin to oral sulfony-
lureas in patients with diabetes due to Kir62 mutations. N Engl J Med. 
2006;355(5):467–477.
 71. Lang VY, Fatehi M, Light PE. Pharmacogenomic analysis of ATP-
sensitive potassium channels coexpressing the common type 2 dia-
betes risk variants E23K and S1369A. Pharmacogenet Genomics. 
2012;22(3):206–214.
 72. Zhang H, Liu X, Kuang H, Yi R, Xing H. Association of sulfonylurea 
receptor 1 genotype with therapeutic response to gliclazide in type 2 
diabetes. Diabetes Res Clin Pract. 2007;77(1):58–61.
 73. Feng Y, Mao G, Ren X, et al. Ser1369Ala variant in sulfonylu-
rea receptor gene ABCC8 is associated with antidiabetic efficacy 
of gliclazide in Chinese type 2 diabetic patients. Diabetes Care. 
2008;31(10):1939–1944.
 74. Li Q, Chen M, Zhang R, et al. KCNJ11 E23K variant is associated 
with the therapeutic effect of sulphonylureas in Chinese type 2 diabetic 
patients. Clin Exp Pharmacol Physiol. 2014;41(10):748–754.
 75. Javorsky M, Klimcakova L, Schroner Z, et al. KCNJ11 gene E23K 
variant and therapeutic response to sulfonylureas. Eur J Intern Med. 
2012;23(3):245–249.
 76. Gloyn AL, Hashim Y, Ashcroft SJ, et al; UK Prospective Diabetes 
Study (UKPDS 53). Association studies of variants in promoter and 
coding regions of beta-cell ATP-sensitive K-channel genes SUR1 
and Kir62 with Type 2 diabetes mellitus (UKPDS 53). Diabet Med. 
2001;18(3):206–212.
 77. Sesti G, Laratta E, Cardellini M, et al. The E23K variant of KCNJ11 
encoding the pancreatic beta-cell adenosine 5’-triphosphate-sensitive 
potassium channel subunit Kir62 is associated with an increased risk 
of secondary failure to sulfonylurea in patients with type 2 diabetes. 
J Clin Endocrinol Metab. 2006;91(6):2334–2339.
 78. Ragia G, Tavridou A, Petridis I, Manolopoulos VG. Association of 
KCNJ11 E23K gene polymorphism with hypoglycemia in sulfo-
nylurea-treated type 2 diabetic patients. Diabetes Res Clin Pract. 
2012;98(1):119–124.
 79. Shu L, Sauter NS, Schulthess FT, Matveyenko AV, Oberholzer J, Maedler K. 
Transcription factor 7-like 2 regulates beta-cell survival and function 
in human pancreatic islets. Diabetes. 2008;57(3):645–653.
 80. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription 
factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat 
Genet. 2006;38(3):320–323.
 81. Pearson ER, Donnelly LA, Kimber C, et al. Variation in TCF7L2 
influences therapeutic response to sulfonylureas: a GoDARTs study. 
Diabetes. 2007;56(8):2178–2182.
 82. Schroner Z, Javorsky M, Tkacova R, et al. Effect of sulphonylurea treat-
ment on glycaemic control is related to TCF7L2 genotype in patients 
with type 2 diabetes. Diabetes Obes Metab. 2011;13(1):89–91.
 83. Javorský M, Babjaková E, Klim áková L, et al. Association between 
TCF7L2 genotype and glycemic control in diabetic patients treated with 
gliclazide. Int J Endocrinol. 2013;2013:374858.
 84. Holstein A, Hahn M, Körner A, Stumvoll M, Kovacs P. TCF7L2 and 
therapeutic response to sulfonylureas in patients with type 2 diabetes. 
BMC Med Genet. 2011;12:30.
 85. Bachmakov I, Glaeser H, Fromm MF, König J. Interaction of oral antidi-
abetic drugs with hepatic uptake transporters: focus on organic anion 
transporting polypeptides and organic cation transporter 1. Diabetes. 
2008;57(6):1463–1469.
 86. Niemi M, Backman JT, Kajosaari LI, et al. Polymorphic organic 
anion transporting polypeptide 1B1 is a major determinant of 
repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005;77(6): 
468–478.
 87. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. Different 
effects of SLCO1B1 polymorphism on the pharmacokinetics and 
pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol. 
2008;48(3):311–321.
 88. Zhang W, He YJ, Han CT, et al. Effect of SLCO1B1 genetic polymor-
phism on the pharmacokinetics of nateglinide. Br J Clin Pharmacol. 
2006;62(5):567–572.
 89. Cheng Y, Wang G, Zhang W, Fan L, Chen Y, Zhou HH. Effect of 
CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and 
pharmacodynamics of nateglinide in healthy Chinese male volunteers. 
Eur J Clin Pharmacol. 2013;69(3):407–413.
 90. Kalliokoski A, Backman JT, Neuvonen PJ, Niemi M. Effects of the 
SLCO1B1*1B haplotype on the pharmacokinetics and pharmaco-
dynamics of repaglinide and nateglinide. Pharmacogenet Genomics. 
2008;18(11):937–942.
 91. Kirchheiner J, Meineke I, Müller G, et al. Influence of CYP2C9 and 
CYP2D6 polymorphisms on the pharmacokinetics of nateglinide 
in genotyped healthy volunteers. Clin Pharmacokinet. 2004;43(4): 
267–278.
 92. Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ. 
Polymorphism in CYP2C8 is associated with reduced plasma concentra-
tions of repaglinide. Clin Pharmacol Ther. 2003;74(4):380–387.
 93. He YY, Zhang R, Shao XY, et al. Association of KCNJ11 and ABCC8 
genetic polymorphisms with response to repaglinide in Chinese diabetic 
patients. Acta Pharmacol Sin. 2008;29(8):983–989.
 94. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperg-
lycemia in type 2 diabetes, 2015: a patient-centered approach. Update 
to a position statement of the American Diabetes Association and 
the European Association for the Study of Diabetes. Diabetes Care. 
2015;38:140–149.
 95. Levin D, Bell S, Sund R, et al; Scottish Diabetes Research Network 
Epidemiology Group; Diabetes and Cancer Research Consortium. Pio-
glitazone and bladder cancer risk: a multipopulation pooled, cumulative 
exposure analysis. Diabetologia. 2015;58(3):493–504.
 96. Lewis JM, Ferrara A, Peng T, et al. Risk of bladder cancer among dia-
betic patients treated with pioglitazone interim report of a longitudinal 
cohort study. Diabetes Care. 2008;34:916–922.
 97. Kalliokoski A, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism 
and oral antidiabetic drugs. Basic Clin Pharmacol Toxicol. 2010; 
107(4):775–781.
 98. Kirchheiner J, Thomas S, Bauer S, et al. Pharmacokinetics and phar-
macodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin 
Pharmacol Ther. 2006;80(6):657–667.
Pharmacogenomics and Personalized Medicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/pharmacogenomics-and-personalized-medicine-journal
Pharmacogenomics and Personalized Medicine is an international, peer-
reviewed, open access journal characterizing the influence of genotype 
on pharmacology leading to the development of personalized treatment 
programs and individualized drug selection for improved safety, efficacy 
and sustainability. This journal is indexed on the American Chemical 
Society’s Chemical Abstracts Service (CAS). The manuscript manage-
ment system is completely online and includes a very quick and fair 
peer-review system, which is all easy to use. Visit http://www.dovepress.
com/testimonials.php to read real quotes from published authors.
Pharmacogenomics and Personalized Medicine 2016: 9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
29
A review on pharmacogenetics in type 2 diabetes
 99. Aquilante CL, Bushman LR, Knutsen SD, Burt LE, Rome LC, 
Kosmiski LA. Influence of SLCO1B1 and CYP2C8 gene polymor-
phisms on rosiglitazone pharmacokinetics in healthy volunteers. Hum 
Genomics. 2008;3(1):7–16.
 100. Aquilante CL, Kosmiski LA, Bourne DW, et al. Impact of the 
CYP2C8 *3 polymorphism on the drug-drug interaction between gemfi-
brozil and pioglitazone. Br J Clin Pharmacol. 2013;75(1):217–226.
 101. Tornio A, Niemi M, Neuvonen PJ, Backman JT. Trimethoprim and 
the CYP2C8*3 allele have opposite effects on the pharmacokinetics 
of pioglitazone. Drug Metab Dispos. 2008;36(1):73–80.
 102. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. No significant 
effect of SLCO1B1 polymorphism on the pharmacokinetics of 
rosiglitazone and pioglitazone. Br J Clin Pharmacol. 2008;65(1): 
78–86.
 103. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common 
PPARgamma Pro12Ala polymorphism is associated with decreased 
risk of type 2 diabetes. Nat Genet. 2000;26(1):76–80.
 104. Hsieh MC, Lin KD, Tien KJ, et al. Common polymorphisms of the 
peroxisome proliferator-activated receptor-gamma (Pro12Ala) and 
peroxisome proliferator-activated receptor-gamma coactivator-1 
(Gly482Ser) and the response to pioglitazone in Chinese patients with 
type 2 diabetes mellitus. Metabolism. 2010;59(8):1139–1144.
 105. Pei Q, Huang Q, Yang GP, et al. PPAR-γ2 and PTPRD gene polymor-
phisms influence type 2 diabetes patients’ response to pioglitazone in 
China. Acta Pharmacol Sin. 2013;34(2):255–261.
 106. Kang ES, Park SY, Kim HJ, et al. Effects of Pro12Ala polymor-
phism of peroxisome proliferator-activated receptor gamma2 gene 
on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther. 
2005;78(2):202–208.
 107. Bailey SD, Xie C, Do R, et al. Variation at the NFATC2 locus increases 
the risk of thiazolidinedione-induced edema in the Diabetes REduction 
Assessment with ramipril and rosiglitazone Medication (DREAM) 
study. Diabetes Care. 2010;33(10):2250–2253.
 108. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 
receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 dia-
betes. Lancet. 2006;368(9548):1696–1705.
 109. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 
2007;87(4):1409–1439.
 110. Sathananthan A, Man CD, Micheletto F, et al. Common genetic 
variation in GLP1R and insulin secretion in response to exog-
enous GLP-1 in nondiabetic subjects: a pilot study. Diabetes Care. 
2010;33(9):2074–2076.
 111. ’t Hart LM, Fritsche A, Nijpels G, et al. The CTRB1/2 locus affects 
diabetes susceptibility and treatment via the incretin pathway. Diabetes. 
2013;62(9):3275–3281.
 112. Scheen AJ. Pharmacokinetics, pharmacodynamics and clinical use of 
SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic 
kidney disease. Clin Pharmacokinet. 2015;54(7):691–708.
 113. Francke S, Mamidi RN, Solanki B, et al. In vitro metabolism of cana-
gliflozin in human liver, kidney, intestine microsomes, and recombinant 
uridine diphosphate glucuronosyltransferases (UGT) and the effect 
of genetic variability of UGT enzymes on the pharmacokinetics of 
canagliflozin in humans. J Clin Pharmacol. 2015;55(9):1061–1072.
 114. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose 
co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 
diabetes mellitus. Drugs. 2015;75(1):33–59.
 115. van den Heuvel LP, Assink K, Willemsen M, Monnens L. Autosomal 
recessive renal glucosuria attributable to a mutation in the sodium 
glucose cotransporter (SGLT2). Hum Genet. 2002;111(6):544–547.
 116. Calado J, Soto K, Clemente C, Correia P, Rueff J. Novel compound 
heterozygous mutations in SLC5A2 are responsible for autosomal 
recessive renal glucosuria. Hum Genet. 2004;114(3):314–316.
 117. Rafiq M, Flanagan SE, Patch AM, et al; Neonatal Diabetes Inter-
national Collaborative Group. Effective treatment with diabetes 
due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care. 
2008;32(2):204–209.
